Paliperidone으로 교체한 조현병 환자에서 8주 후 Metabolic Parameter와 Positive and Negative Syndrome Scale (PANSS) 점수의 변화 = Changes in the Metabolic Parameters and Positive and Negative Syndrome Scale (PANSS) Scores of Patients with Schizophrenia 8 Weeks after Switching to Paliperidone

다국어 초록 (Multilingual Abstract)

Objectives : The purpose of this study was to examine the changes in metabolic parameters and Positive and Negative Syndrome Scale (PANSS) scores of patients previously treated with atypical antipsychotic drugs other than paliperidone, after 8 weeks of treatment with paliperidone. Methods : Changes in body weight, body mass index, leptin, lipid levels, fasting glucose, and PANSS scores of patients who switched from other atypical antipsychotic drugs to paliperidone were measured after 8 weeks of treatment with paliperidone. We compared these results with those of patients who had not been treated with antipsychotic drugs for at least 2 weeks prior to treatment with paliperidone (antipsychotic drug-free patients). Results : The antipsychotic drug-free group (n = 9) did not show significant changes in metabolic parameters, but showed a significant improvement in total and subscale scores of PANSS. In the group that switched from other atypical antipsychotic drugs to paliperidone (n = 13), body weight, body mass index and fasting glucose level significantly increased, while total and subscale scores of PANSS significantly improved. Conclusions : Paliperidone treatment will benefit patients with schizophrenia who have been antipsychotic drug-free or who have had difficulty with other atypical antipsychotic drugs, with regard to their psychopathological state. However, if patients have been treated with other atypical antipsychotic drugs before switching to paliperidone, they could gain body weight or their fasting glucose level could increase over a short period because of a change in receptor number and sensitivity caused by the previously prescribed antipsychotic drugs, and hence, paliperidone should be prescribed with caution for these patients.

참고문헌 (Reference)

1 Samaha AN, "“Breakthrough” dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time" 27 : 2979-2986, 2007

2 Kane J, "Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial" 90 : 147-161, 2007

3 Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia" 13 : 261-276, 1987

4 de Leon J, "The pharmacokinetics of paliperidone versus risperidone" 51 : 80-88, 2010

5 Son HI, "The effect of atypical antipsychotics on weight" 11 : 135-144, 2004

6 Masaki T, "Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice" 50 : 385-391, 2001

7 Silvestre JS, "Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes" 27 : 289-304, 2005

8 Matsui-Sakata A, "Receptor occupancy-based analysis of the contributions of various receptors to antipsychoticsinduced weight gain and diabetes mellitus" 20 : 368-378, 2005

9 Marangell LB, "Psychopharmacology and Electroconvulsive Therapy, In Textbook of clinical psychiatry. Vol II" American Psychiatric Publishing 1047-1150, 2003

10 Templeman LA, "Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a firstepisode psychosis" 15 : 195-200, 2005

11 Cho HS, "Pharmacological Actions of Antipsychotics, In Clinical Neuropsychopharmacology" ML Communications 115-133, 2009

12 Canuso CM, "Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone" 23 : 209-215, 2008

13 Marino J, "Paliperidone extended-release for the treatment of schizophrenia" 28 : 1283-1298, 2008

14 김양래, "Olanzapine을 투여 받은 정신분열병 환자의 체중, 체질량지수, 렙틴, 인슐린, 공복시 혈당의 변화" 대한신경정신의학회 40 (40): 1240-1246, 2001

15 Mertens C, "Long-term treatment of chronic schizophrenic patients with risperidone, In Risperidone: Major Progress in Antipsychotic Treatment" Oxford Clinical Communication 44-48, 1991

16 Silvestri S, "Increased dopamine D2 receptor binding after longterm treatment with antipsychotics in humans: a clinical PET study" 152 : 174-180, 2000

17 Kim SF, "From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase" 104 : 3456-3459, 2007

18 Davidson M, "Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study" 93 : 117-130, 2007

19 McEvoy JP, "Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, doubleblind 52-week comparison" 164 : 1050-1060, 2007

20 Lee MS, "Efficacy and safety profile of risperidone in schizophrenia: long-term follow-up study" 38 : 116-127, 1999

21 Marder SR, "Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study" 62 : 1363-1370, 2007

22 Choi YK, "Effects of repeated risperidone exposure on serotonin receptor subtypes in developing rats" 20 : 187-194, 2010

23 Dirks B, "Effects of paliperidone ER in patients with schizophrenia previously treated with olanzapine" 2007

24 Graham KA, "Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis" 162 : 118-123, 2005

25 Turkoz I, "Direct and indirect effects of paliperidone extended-release tablets on negative symptoms of schizophrenia" 4 : 949-958, 2008

26 Wetterling T, "Bodyweight gain with atypical antipsychotics. A comparative review" 24 : 59-73, 2001

27 Nasrallah HA, "Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles" 13 : 27-35, 2008

28 Reynolds GP, "Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism" 359 : 2086-2087, 2002

29 Arulmozhi DK, "Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice" 79 : 1865-1872, 2006

30 Melkersson K, "Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications" 64 : 701-723, 2004

31 Vermeir M, "Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans" 36 : 769-779, 2008

32 Minokoshi Y, "AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus" 428 : 569-574, 2004

33 이종범, "2세대 항정신병 약물의 대사증후군" 대한생물치료정신의학회 13 (13): 138-146, 2007